Navigation Links
Generex Provides Corporate Update
Date:8/2/2011

the extant Phase II study.  Results from the ongoing Phase II study will be used for patient number adjustment, thereby assuring statistical significance in the Phase III trial.  Also, the Company recently completed a Phase I study of the AE37 vaccine for prostate cancer and a Phase I study of the AE37 vaccine for ovarian cancer is underway.  AE37 represents a new class of self-potentiating peptide vaccines designed to stimulate the immune system to specifically recognize and kill cancer cells.  
  • Valuation of the AE37 breast cancer vaccine.  Recently, a leading national independent valuation firm specializing in pharmaceuticals prepared an appraisal for the Company's AE37 breast cancer vaccine and arrived at a value of $301 million at the vaccines current stage of clinical development.  Given that Herceptin®, which is only available to treat roughly one-third of the patients that would be eligible for AE37, had sales of $1.8 Billion in 2008, the Company believes the estimated valuation of its breast cancer vaccine to be conservative.  The report did not include or evaluate the potential use of AE37 for treatment of other cancers expressing lower levels of HER2 than are required for use with Herceptin®, such as prostate, ovarian, colon, and lung tumors.  

  • Strengthened Product Pipeline.  In addition to the clinical advancement of Generex Oral-lyn™ and its oncology product pipeline, the Company has been focusing its efforts on leveraging both its RapidMist™ buccal drug delivery technology and it immunotherapeutic vaccine platform by way of partnering with leading research and development companies.  A collaboration with RXi Pharmaceuticals (NasdaqCM: RXII) to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immun
    '/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) ... of Pharma in 2014 - a Perspective of Mental ... their offering. For the first time, in ... reputation of the pharmaceutical industry held by patient groups ... of patient organisations representing all therapy areas. ...
(Date:4/16/2015)... 2015 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for the treatment of central ... for the first quarter of 2015 on Wednesday, May ... The Company will host a conference call at 4:30 ... Vanda management will discuss the first quarter 2015 financial ...
(Date:4/16/2015)... April 16, 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... 31, 2015 on Wednesday, May 6, 2015, following the close ... an investor conference call and live webcast on the same ... update and discuss the financial results.  To ... , under the "Investors" link.  Please log onto the webcast ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3
... on Valopicitabine Combined,with an Investigational Protease Inhibitor, ... Pharmaceuticals, Inc. today announced results from two ... valopicitabine (NM283) and,pegylated interferon alfa-2a (Pegasys(R)) in ... the genotype-1,strain of the hepatitis C virus ...
... /PRNewswire-FirstCall/ --,CuraGen Corporation announced today that new ... (HDAC) inhibitor being,investigated for the treatment of ... the prevention of severe oral mucositis,will be ... Cancer,Research (AACR) 2007 Annual Meeting in Los ...
Cached Medicine Technology:Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
(Date:4/19/2015)... Broccoli sprout extract protects against oral cancer in ... healthy human volunteers, the University of Pittsburgh Cancer ... announced today at the American Association for Cancer ... The promising results will be further explored in a ... risk for head and neck cancer recurrence later this ...
(Date:4/19/2015)... 2015 New court documents issued by ... that Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) continue to mount ... District of South Carolina. According to the April 15th ... in the proceeding on behalf of individuals who allegedly ... the cholesterol-lowering statin. This represents an increase of 110 ...
(Date:4/19/2015)... (PRWEB) April 19, 2015 Family and friends ... for Brains in Memory of Brad Baddeley event to ... Aneurysm Foundation. , Bowling for Brains is cheduled to take ... 4700 Dudley Street in Lincoln, Nebraska. Participants may arrive at ... to 3:00pm. , The cost is only $4 per game ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Carinsurancequotesinfo.com has ... insurance can cover physical injuries caused by a ... excellent financial coverage for a vehicle. A policy can ... by an accident. Drivers should always carry appropriate coverage ... insurance policy can be bought with several important riders ...
(Date:4/18/2015)... Review of Ophthalmology magazine and Abbot ... Success’ program for cataract surgeons attending the American Society ... where eye surgeon Jeffrey L. Martin, MD will serve ... Martin is the Managing Partner of North Shore Eye ... Martin to lead this year’s discussion on the latest ...
Breaking Medicine News(10 mins):Health News:Preventing Cancer with Broccoli Sprout Extract 2Health News:Preventing Cancer with Broccoli Sprout Extract 3Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 2Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 3Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2
... ULURU Inc. (Amex:,ULU) announced today that its ... Back Offer, whereby the Company will offer to ... shares of common stock. This,program reflects ULURU,s desire ... communications costs and the potential costs,which often deter ...
... may actually be in the candy dish. In ... Heart Association conference in Orlando shows that people at ... kept the wrappers in plain sight The sneakiest, creepiest surprise ... In a study being presented this Saturday ...
... almost half of patients, study found , TUESDAY, Oct. 30 ... for treating people with what,s known as cytokine-refractory metastatic kidney ... poor response to drug treatment. , Axitinib is a selective ... receptors 1, 2 and 3. , As reported in ...
... Pa., Oct. 30 ViroPharma Incorporated,(Nasdaq: VPHM ) reported today ... 2007. Key events since June 30, 2007 include:, Clinical:, ... Camvia(TM) (maribavir) in liver transplant patients; ... of Camvia in stem cell transplant patients; ...
... TORONTO, Oct. 30 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer ... room, will host a conference call and live webcast,to discuss the ... ... 4:30 pm, Eastern Time, Dial ...
... Oct. 30 GeneGo, Inc., the leading,systems biology ... its flagship data analysis suite MetaCore(TM). The platform,will ... is designed for,functional analysis of biological and chemistry ... autoimmune programs. "We are very pleased that ...
Cached Medicine News:Health News:ULURU Inc. Announces Odd-Lot Buy Back Offer 2Health News:Food 'tricks' that combat sneaky, creepy Halloween treats 2Health News:New Drug Promising Against Tough-to-Treat Kidney Cancer 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:Novadaq announces third quarter 2007 conference call and webcast 2Health News:Novadaq announces third quarter 2007 conference call and webcast 3
... This test device is ... detection of IgG and IgM ... human serum. The test is ... for diagnosis of Dengue viral ...
... Gonorrhea is intended for the immunochromatographic, ... swab samples.,Smart Strip Gonorrhea is based ... for the determination of gonorrhea antigen ... from urinary system as an aid ...
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: